GlassScriptPhysician profile
Vivian Charneco
NPI 1144322025
$13,657.92
in general payments reported to CMS, 2019-2025
25 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $2,141 · 2021: $1,043 · 2022: $2,030 · 2023: $2,524 · 2024: $2,425 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,980.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,798.36 | 2021-2025 | Vraylar, Ubrelvy |
| Neuronetics, INC. | $2,390.69 | 2019-2024 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $1,632.62 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $1,337.48 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $848.05 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $832.12 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $791.88 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $788.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $472.38 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $343.22 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $316.23 | 2025 | Cobenfy |
| Allergan, INC. | $178.80 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $177.06 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $174.14 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $108.67 | 2019-2024 | Fanapt, Hetlioz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $94.78 | 2021 | |
| Ironshore Pharmaceuticals INC. | $84.99 | 2022-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $78.65 | 2019 | |
| Tris Pharma INC | $72.54 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Almatica Pharma LLC | $39.42 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $37.69 | 2024-2025 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $20.13 | 2023 | Quviviq |
| Indivior INC. | $15.37 | 2023 | Perseris |
| Vertical Pharmaceuticals, LLC | $12.88 | 2019 | |
| Neos Therapeutics, LP | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivian Charneco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.